Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1

Area of Science:

• Neuroscience
• Biotechnology
• Genetics

Background:

• The neurovascular unit plays a critical role in neurodegenerative diseases.
• Vascular endothelial growth factor (VEGF) is suppressed in spinocerebellar ataxia type 1 (SCA1), and its replenishment reverses cerebellar pathology in mouse models.
• Previous VEGF therapy used costly, unstable, and immunogenic recombinant protein.

Purpose of the Study:

• To develop a more viable therapeutic strategy for SCA1 using a synthetic VEGF peptide amphiphile.
• To evaluate the efficacy and safety of nano-VEGF in SCA1 mouse models.

Main Methods:

• A synthetic VEGF peptide amphiphile was developed to self-assemble into nanoparticles (nano-VEGF).
• The neurotrophic and angiogenic properties of nano-VEGF were assessed.
• The therapeutic effects of nano-VEGF were evaluated in SCA1 mice, including at advanced disease stages.

Main Results:

• Nano-VEGF demonstrated potent neurotrophic and angiogenic properties.
• The therapy was well-tolerated in SCA1 mice.
• Nano-VEGF administration led to functional improvements in SCA1 mice, even when given late in the disease progression.

Conclusions:

• Synthetic nano-VEGF offers a potent, well-tolerated, and effective therapeutic strategy for SCA1.
• This nanoparticle approach can be generalized to other neurotrophic factors for treating neurodegenerative conditions.
• Nano-VEGF represents a novel and potentially viable therapeutic avenue for neurological disorders.